Relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy: A meta-analysis.

IF 2.6 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-05-24 DOI:10.5306/wjco.v16.i5.102611

Ling-Hong Wan, Bi-Jing Mao, Bin Wang

{"title":"Relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy: A meta-analysis.","authors":"Ling-Hong Wan, Bi-Jing Mao, Bin Wang","doi":"10.5306/wjco.v16.i5.102611","DOIUrl":null,"url":null,"abstract":"Background: Many studies have found that sarcopenia is related to the survival of patients with liver cancer, which may lead to worse prognosis.Aim: To investigate the relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy by meta-analysis.Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for clinical studies on the relationship between skeletal muscle index (SMI) and the prognosis of patients with liver cancer receiving targeted therapy from inception to March 1, 2022. Meta-analysis and sensitivity analysis of the data were performed using Stata 16.0 software.Results: A total of 6877 studies were searched, and finally 12 articles with 1715 cases were included. Meta-analysis result of 8 articles showed that compared with non-low SMI group, the overall survival (OS) of patients with liver cancer in the low SMI group was significantly shorter (hazard ratio = 1.60, 95% confidence interval: 1.44-1.77, P = 0.000). Meta-analysis result of 4 articles showed that, compared with low SMI group, patients in the non-low SMI group had longer OS (hazard ratio = 0.59, 95% confidence interval: 0.38-0.91, P = 0.018).Conclusion: Skeletal muscle mass is positively correlated with OS in patients with liver cancer receiving targeted therapy.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"102611"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149824/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i5.102611","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Many studies have found that sarcopenia is related to the survival of patients with liver cancer, which may lead to worse prognosis.

Aim: To investigate the relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy by meta-analysis.

Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for clinical studies on the relationship between skeletal muscle index (SMI) and the prognosis of patients with liver cancer receiving targeted therapy from inception to March 1, 2022. Meta-analysis and sensitivity analysis of the data were performed using Stata 16.0 software.

Results: A total of 6877 studies were searched, and finally 12 articles with 1715 cases were included. Meta-analysis result of 8 articles showed that compared with non-low SMI group, the overall survival (OS) of patients with liver cancer in the low SMI group was significantly shorter (hazard ratio = 1.60, 95% confidence interval: 1.44-1.77, P = 0.000). Meta-analysis result of 4 articles showed that, compared with low SMI group, patients in the non-low SMI group had longer OS (hazard ratio = 0.59, 95% confidence interval: 0.38-0.91, P = 0.018).

Conclusion: Skeletal muscle mass is positively correlated with OS in patients with liver cancer receiving targeted therapy.

查看原文本刊更多论文

接受靶向治疗的肝癌患者骨骼肌质量与预后的关系：一项荟萃分析

背景：许多研究发现，肌肉减少症与肝癌患者的生存有关，可能导致预后较差。目的：通过荟萃分析，探讨肝癌靶向治疗患者骨骼肌质量与预后的关系。方法：检索PubMed、Embase、Cochrane Library和Web of Science，检索自研究开始至2022年3月1日接受靶向治疗的肝癌患者骨骼肌指数（SMI）与预后关系的临床研究。采用Stata 16.0软件对数据进行meta分析和敏感性分析。结果：共检索6877篇文献，最终纳入12篇文献，1715例病例。8篇文章的meta分析结果显示，与非低SMI组相比，低SMI组肝癌患者的总生存期（OS）显著缩短（风险比= 1.60,95%可信区间：1.44-1.77,P = 0.000）。4篇文章的meta分析结果显示，与低SMI组相比，非低SMI组患者的OS更长（风险比= 0.59,95%可信区间：0.38-0.91,P = 0.018）。结论：接受靶向治疗的肝癌患者骨骼肌质量与OS呈正相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.